Multiple sclerosis: glatiramer acetate induces anti-inflammatory T cells in the cerebrospinal fluid

Abstract

Glatiramer acetate (GA) is believed to induce GA-reactive T cells that secrete anti-inflammatory cytokines at the site of inflammation in multiple sclerosis (MS). However, GA-reactive T cells have not been established from the intrathecal compartment of MS patients, and intrathecal T cells may differ from T cells in blood. Here, we compared the phenotype of GA-reactive T cells from the cerebrospinal fluid (CSF) and blood of five MS patients treated with GA for 3-36 months, and in three of these patients also before treatment. From the CSF of these patients, all 22 T cell lines generated before and all 38 T cell lines generated during treatment were GA-reactive. GA treatment induced a more pronounced anti-inflammatory profile of GA-reactive T cell lines from CSF than from blood. While GA-reactive T cell clones from CSF were restricted by either human leukocyte antigen (HLA) -DR or HLA-DP, only HLA-DR restricted GA-reactive T cell clones were detected in blood. No cross reactivity with myelin proteins was detected in GA-reactive T cell lines or clones from CSF. These results suggest that a selected subset of GA-reactive T cells are present in the intrathecal compartment, and support an anti-inflammatory mechanism of action for GA.

Keywords

multiple sclerosis;immunology;glatiramer acetate;disease modifying therapies

Get full access to this article

View all access options for this article.

References

1 Johnson KP Brooks BR Cohen JA . Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group. Neurology 1995; 45: 1268 – 1276 .

2 Johnson KP Brooks BR Cohen JA . Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability. Copolymer 1 Multiple Sclerosis Study Group. Neurology 1998; 50: 701 – 708 .

3 Fridkis-Hareli M Strominger JL . Promiscuous binding of synthetic copolymer 1 to purified HLA-DR molecules. J Immunol 1998; 160: 4386 – 4397 .

4 Sanna A Fois ML Arru G . Glatiramer acetate reduces lymphocyte proliferation and enhances IL-5 and IL-13 production through modulation of monocyte-derived dendritic cells in multiple sclerosis. Clin Exp Immunol 2006; 143: 357 – 362 .

5 Weber MS Prod'homme T Youssef S . Type II monocytes modulate T cell-mediated central nervous system autoimmune disease. Nat Med 2007; 13: 935 – 943 .

6 Kim HJ Ifergan I Antel JP . Type 2 monocyte and microglia differentiation mediated by glatiramer acetate therapy in patients with multiple sclerosis. J Immunol 2004; 172: 7144 – 7153 .

7 Ziemssen T Schrempf W . Glatiramer acetate: mechanisms of action in multiple sclerosis. Int Rev Neurobiol 2007; 79: 537 – 570 .

8 Ragheb S Abramczyk S Lisak D Lisak R . Long-term therapy with glatiramer acetate in multiple sclerosis: effect on T cells. Mult Scler 2001; 7: 43 – 47 .

9 Chen M Conway K Johnson KP Martin R Dhib-Jalbut S . Sustained immunological effects of Glatiramer acetate in patients with multiple sclerosis treated for over 6 years. J Neurol Sci 2002; 201: 71 – 77 .

10.

10 Aharoni R Teitelbaum D Sela M Arnon R . Copolymer 1 induces T cells of the T helper type 2 that crossreact with myelin basic protein and suppress experimental autoimmune encephalomyelitis. Proc Natl Acad Sci U S A 1997; 94: 10821 – 10826 .

11.

11 Neuhaus O Farina C Yassouridis A . Multiple sclerosis: comparison of copolymer-1-reactive T cell lines from treated and untreated subjects reveals cytokine shift from T helper 1 to T helper 2 cells. Proc Natl Acad Sci U S A 2000; 97: 7452 – 7457 .

12.

12 Duda PW Schmied MC Cook SL Krieger JI Hafler DA . Glatiramer acetate (Copaxone) induces degenerate, Th2-polarized immune responses in patients with multiple sclerosis. J Clin Invest 2000; 105: 967 – 976 .

13.

13 Aharoni R Teitelbaum D Leitner O Meshorer A Sela M Arnon R . Specific Th2 cells accumulate in the central nervous system of mice protected against experimental autoimmune encephalomyelitis by copolymer 1. Proc Natl Acad Sci U S A 2000; 97: 11472 – 11477 .

14.

14 Aharoni R Meshorer A Sela M Arnon R . Oral treatment of mice with copolymer 1 (glatiramer acetate) results in the accumulation of specific Th2 cells in the central nervous system. J Neuroimmunol 2002; 126: 58 – 68 .

15.

15 Ziemssen T Kumpfel T Klinkert WE Neuhaus O Hohlfeld R . Glatiramer acetate-specific T helper 1- and 2-type cell lines produce BDNF: implications for multiple sclerosis therapy. Brain-derived neurotrophic factor. Brain 2002; 125: 2381 – 2391 .

16.

16 Kipnis J Yoles E Porat Z . T cell immunity to copolymer 1 confers neuroprotection on the damaged optic nerve: possible therapy for optic neuropathies. Proc Natl Acad Sci U S A 2000; 97: 7446 – 7451 .

17.

17 Chen M Valenzuela RM Dhib-Jalbut S . Glatiramer acetate-reactive T cells produce brain-derived neurotrophic factor. J Neurol Sci 2003; 215: 37 – 44 .

18.

18 Aharoni R Kayhan B Eilam R Sela M Arnon R . Glatiramer acetate-specific T cells in the brain express T helper 2/3 cytokines and brain-derived neurotrophic factor in situ. Proc Natl Acad Sci U S A 2003; 100: 14157 – 14162 .

19.

19 Kim HJ Biernacki K Prat A Antel JP Bar-Or A . Inflammatory potential and migratory capacities across human brain endothelial cells of distinct glatiramer acetate-reactive T cells generated in treated multiple sclerosis patients. Clin Immunol 2004; 111: 38 – 46 .

20.

20 Lisak RP Zweiman B . In vitro cell-mediated immunity of cerebrospinal-fluid lymphocytes to myelin basic protein in primary demyelinating diseases. N Engl J Med 1977; 297: 850 – 853 .

21.

21 Molberg O McAdam SN Korner R . Tissue transglutaminase selectively modifies gliadin peptides that are recognized by gut-derived T cells in celiac disease. Nat Med 1998; 4: 713 – 717 .

22.

22 Holmoy T Kvale EO Vartdal F . Cerebrospinal fluid CD4+ T cells from a multiple sclerosis patient cross-recognize Epstein-Barr virus and myelin basic protein. J Neurovirol 2004; 10: 278 – 283 .

23.

23 Zhang J Markovic-Plese S Lacet B Raus J Weiner HL Hafler DA . Increased frequency of interleukin 2-responsive T cells specific for myelin basic protein and proteolipid protein in peripheral blood and cerebrospinal fluid of patients with multiple sclerosis. J Exp Med 1994; 179: 973 – 984 .

24.

24 Crawford MP Yan SX Ortega SB . High prevalence of autoreactive, neuroantigen-specific CD8+ T cells in multiple sclerosis revealed by novel flow cytometric assay. Blood 2004; 103: 4222 – 4231 .

25.

25 Holmoy T Fredriksen AB Thompson KM Hestvik AL Bogen B Vartdal F . Cerebrospinal fluid T cell clones from patients with multiple sclerosis: recognition of idiotopes on monoclonal IgG secreted by autologous cerebrospinal fluid B cells. Eur J Immunol 2005; 35: 1786 – 1794 .

26.

26 Bettelli E Oukka M Kuchroo VK. T . (H)-17 cells in the circle of immunity and autoimmunity. Nat Immunol 2007; 8: 345 – 350 .

27.

27 Fitch FW; Gajewski TF; . In vitro assays for mouse lymphocyte function. Current Protocols in Immunology. New York: Wiley 1997; 3.13.1–3.13.4

28.

28 Dabbert D Rosner S Kramer M . Glatiramer acetate (copolymer-1)-specific, human T cell lines: cytokine profile and suppression of T cell lines reactive against myelin basic protein. Neurosci Lett 2000; 289: 205 – 208 .

29.

29 Burns J Krasner LJ Guerrero F . Human cellular immune response to copolymer I and myelin basic protein. Neurology 1986; 36: 92 – 94 .

30.

30 Sospedra M Martin R . Immunology of multiple sclerosis. Annu Rev Immunol 2005; 23: 683 – 747 .

31.

31 Hickey WF Hsu BL Kimura H . T lymphocyte entry into the central nervous system. J Neurosci Res 1991; 28: 254 – 260 .

32.

32 Gran B Tranquill LR Chen M . Mechanisms of immunomodulation by glatiramer acetate. Neurology 2000; 55: 1704 – 1714 .

33.

33 Lobel E Riven-Kreitman R Amselem A Pinchasi I . Copolymer-1. Drugs Future 1996; 21: 131 – 134 .

34.

34 Duda PW Krieger JI Schmied MC Balentine C Hafler DA . Human and murine CD4 T cell reactivity to a complex antigen: recognition of the synthetic random polypeptide glatiramer acetate. J Immunol 2000; 165: 7300 – 7307 .

35.

35 Biegler BW Yan SX Ortega SB Tennakoon DK Racke MK Karandikar NJ . Glatiramer acetate (GA) therapy induces a focused, oligoclonal CD8+ T cell repertoire in multiple sclerosis. J Neuroimmunol 2006; 180: 159 – 171 .

36.

36 Hestvik AL Vartdal F Fredriksen AB . T cells from multiple sclerosis patients recognize multiple epitopes on Self-IgG. Scand J Immunol 2007; 66: 393 – 401 .

37.

37 Lisak RP Zweiman B Blanchard N Rorke LB . Effect of treatment with Copolymer 1 (Cop-1) on the in vivo and in vitro manifestations of experimental allergic encephalomyelitis (EAE). J Neurol Sci 1983; 62: 281 – 293 .

38.

38 Wucherpfennig KW Strominger JL . Molecular mimicry in T cell-mediated autoimmunity: viral peptides activate human T cell clones specific for myelin basic protein. Cell 1995; 80: 695 – 705 .

39.

39 Reiser JB Darnault C Gregoire C . CDR3 loop flexibility contributes to the degeneracy of TCR recognition. Nat Immunol 2003; 4: 241 – 247 .

40.

40 Arnon R Aharoni R . Mechanism of action of glatiramer acetate in multiple sclerosis and its potential for the development of new applications. Proc Natl Acad Sci U S A 2004; 101(Suppl. 2): 14593 – 14598 .

41.

41 Zhang M Chan CC Vistica B Hung V Wiggert B Gery I . Copolymer 1 inhibits experimental autoimmune uveoretinitis. J Neuroimmunol 2000; 103: 189 – 194 .